'Low-risk' prediction rule for pediatric oncology patients presenting with fever and neutropenia

Journal of Clinical Oncology

Volumn 18, Issue 5, 2000, Pages 1012-1019

  Klaassen, Robert J ^a   Goodman, T Robin ^a   Pham, Ba ^a   Doyle, John J ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; FEMALE; FEVER; HUMAN; INFANT; LEUKOCYTE COUNT; MALE; MONOCYTE; NEUTROPENIA; OUTPATIENT; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT PLANNING; VALIDATION PROCESS;

EID: 0034004453     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.5.1012     Document Type: Article

References (29)

1. Pizzo PA, Robichaud KJ, Gill FA, et al: Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 67:194-200, 1979
2. Leong DC, Kinlay S, Ackland S, et al: Low-risk febrile neutropenia in a medical oncology unit. Aust N Z J Med 27:403-407, 1997
3. Hann I, Viscoli C, Paesmans M, et al: A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies - International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 99:580-588, 1997
4. Lucas KG, Brown AE, Armstrong D, et al: The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 77:791-798, 1996
5. From the Centers for Disease Control and Prevention: Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. JAMA 270:1796, 1993
6. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 44:1-13, 1995
7. Lam S, Singer C, Tucci V, et al: The challenge of vancomycin-resistant enterococci: A clinical and epidemiological study. Am J Infect Control 23:170-180, 1995
8. Rackoff WR, Gonin R, Robinson C, et al: Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 14:919-924, 1996
9. Doyle JJ, King SM, Comay SA, et al: Oral antibiotic therapy for "low risk" febrile neutropenic episodes (FNE). Pediatr Res Prog 39:154A, 1996 (abstr)
10. Malik IA, Abbas Z, Karim M: Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 339:1092-1096, 1992 (published erratum appears in Lancet 340:128, 1992)
11. Mustafa MM, Aquino VM, Pappo A, et al: A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 128:847-849, 1996
12. Preis S, Gobel U, Jurgens H: Outpatient treatment with ceftriaxone alone or in combination with teicoplanin in febrile neutropenic children and adolescents with cancer. J Pediatr 130: 500-501, 1997
13. Griffin TC, Buchanan GR: Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: Implications for discontinuation of antibiotics and early discharge from the hospital. J Pediatr 121:28-33, 1992
14. Jones GR, Konsler GK, Dunaway RP, et al: Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr 124:703-708, 1994
15. Talcott JA, Siegel RD, Finberg R, et al: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992
16. From the Immunocompromised Host Society: The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient - Report of a consensus panel. J Infect Dis 161:397-401, 1990
17. Viscoli C, Bruzzi P, Glauser M: An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 31A:2013-2022, 1995
18. Wasson JH, Sox HC, Neff RK, et al: Clinical prediction rules: Applications and methodological standards. N Engl J Med 313:793-799, 1985
19. Pui CH, Boyett JM, Hughes WT, et al: Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336:1781-1787, 1997
20. Blay JY, Chauvin F, Le Cesne A, et al: Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14:636-643, 1996
21. Jones GR, Konsler GK, Dunaway RP, et al: Infection risk factors in febrile, neutropenic children and adolescents. Pediatr Hematol Oncol 13:217-229, 1996
22. Malik IA, Khan WA, Karim M, et al: Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 98:224-231, 1995
23. Goossens W, Van Hove L, Verwilghen RL: Monocyte counting: Discrepancies in results obtained with different automated instruments. J Clin Pathol 44:224-227, 1991
24. Laupacis A, Sekar N, Stiell IG: Clinical prediction rules: A review and suggested modifications of methodological standards. JAMA 277:488-494, 1997
25. Diggle PJ, Liang KY, Zeger SL: Analysis of Longitudinal Data. New York, NY, Oxford University Press, 1994
26. SAS Institute, Inc: SAS System for Mixed Modules. Cary, NC, SAS Institute, Inc, 1996, pp 423-460
27. Malik IA, Khan WA, Aziz Z, et al: Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis 19:522-527, 1994
28. Aquino VM, Tkaczewski I, Buchanan GR: Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 25:74-78, 1997
29. Mullen CA, Buchanan GR: Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and management of the low-risk patient. J Clin Oncol 8:1998-2004, 1990